NO960907D0 - Immunomoduleringssammensetninger fra galle - Google Patents

Immunomoduleringssammensetninger fra galle

Info

Publication number
NO960907D0
NO960907D0 NO960907A NO960907A NO960907D0 NO 960907 D0 NO960907 D0 NO 960907D0 NO 960907 A NO960907 A NO 960907A NO 960907 A NO960907 A NO 960907A NO 960907 D0 NO960907 D0 NO 960907D0
Authority
NO
Norway
Prior art keywords
bile
immunomodulator
composition
relates
immunomodulation
Prior art date
Application number
NO960907A
Other languages
English (en)
Other versions
NO960907L (no
Inventor
Romeo Rang
Original Assignee
Imutec Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imutec Corp filed Critical Imutec Corp
Publication of NO960907D0 publication Critical patent/NO960907D0/no
Publication of NO960907L publication Critical patent/NO960907L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07Retinol compounds, e.g. vitamin A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/075Ethers or acetals
    • A61K31/08Ethers or acetals acyclic, e.g. paraformaldehyde
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37Digestive system
    • A61K35/413Gall bladder; Bile
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/01Hydrolysed proteins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • C07K14/4705Regulators; Modulating activity stimulating, promoting or activating activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Genetics & Genomics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Hematology (AREA)
NO960907A 1993-09-09 1996-03-06 Immunomoduleringssammensetninger fra galle NO960907L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11826993A 1993-09-09 1993-09-09
US15530393A 1993-11-22 1993-11-22
US23172694A 1994-04-04 1994-04-04
PCT/CA1994/000494 WO1995007089A1 (en) 1993-09-09 1994-09-09 Immunomodulating compositions from bile

Publications (2)

Publication Number Publication Date
NO960907D0 true NO960907D0 (no) 1996-03-06
NO960907L NO960907L (no) 1996-04-30

Family

ID=27382133

Family Applications (1)

Application Number Title Priority Date Filing Date
NO960907A NO960907L (no) 1993-09-09 1996-03-06 Immunomoduleringssammensetninger fra galle

Country Status (15)

Country Link
US (1) US6280774B1 (no)
EP (1) EP0717631B1 (no)
JP (1) JP4708511B2 (no)
KR (1) KR100260110B1 (no)
CN (1) CN1132586C (no)
AT (1) ATE244570T1 (no)
AU (1) AU7648994A (no)
CA (1) CA2171281C (no)
DE (1) DE69432930T2 (no)
ES (1) ES2207639T3 (no)
FI (1) FI961109A (no)
HK (1) HK1007922A1 (no)
NO (1) NO960907L (no)
NZ (1) NZ273258A (no)
WO (1) WO1995007089A1 (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0814821A1 (en) * 1995-03-16 1998-01-07 Imutec Pharma Inc. Immunomodulating compositions from bile for the treatment of immune system disorders
WO1998030231A1 (en) 1997-01-07 1998-07-16 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the reduction of food intake
CA2206047A1 (en) * 1997-05-23 1998-11-23 Romeo Rang (Deceased) Immunomodulating compositions for the treatment of viral disorders
NZ516848A (en) * 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
AU2002214876A1 (en) * 2000-11-08 2002-05-21 Lorus Therapeutics Inc. Combination preparation of a biological response modifier and an anticancer agent and uses thereof
ITRM20010688A1 (it) * 2001-11-21 2003-05-21 Univ Roma Composti immunoregolatori.
US20040171522A1 (en) * 2003-02-27 2004-09-02 Yaron Ilan Regulation of immune responses by manipulation of intermediary metabolite levels
WO2005032462A2 (en) 2003-02-27 2005-04-14 Enzo Therapeutics, Inc. Glucocerebroside treatment of disease
US9717754B2 (en) 2003-02-27 2017-08-01 Enzo Therapeutics, Inc. Glucocerebroside treatment of disease
JP4274469B2 (ja) * 2004-01-20 2009-06-10 Okiセミコンダクタ株式会社 データ取り込みクロック補正回路
ES2533970T3 (es) * 2005-03-08 2015-04-16 Aptose Biosciences Inc. Uso de interleucina 17E para el tratamiento de cáncer
GB0513431D0 (en) * 2005-06-30 2005-08-10 Kherion Technology Ltd Prophylactic compositions and uses
CN101629951B (zh) * 2009-08-20 2013-01-02 吴广印 一种人胎盘组织液抗炎作用检测方法
US8236354B1 (en) 2012-02-17 2012-08-07 ZOR Pharmaceuticals, LLC Use of immunomodulators for the treatment of cancer
US8338383B1 (en) 2012-02-17 2012-12-25 Gregory Jr Daniel Tyree Use of immunomodulators for the treatment of cancer

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2046092B (en) 1979-03-05 1983-11-02 Toyama Chemical Co Ltd Pharmaceutical composition containing a lysophospholid and a phospholipid
US4562179A (en) 1982-04-19 1985-12-31 Fujisawa Pharmaceutical Co., Ltd. Phospholipid derivatives, and pharmaceutical composition of the same
US4585762A (en) 1982-07-30 1986-04-29 Fujisawa Pharmaceutical Co., Ltd. Phospholipid derivatives, processes for use thereof and pharmaceutical composition of the same
JPS5984824A (ja) 1982-11-08 1984-05-16 Takeda Chem Ind Ltd 抗腫瘍剤
US4767610A (en) 1984-10-19 1988-08-30 The Regents Of The University Of California Method for detecting abnormal cell masses in animals
US4916249A (en) 1985-07-03 1990-04-10 Hans Brachwitz Glycero-3(2)-phospho-L-serine derivatives and salts thereof
IE59777B1 (en) 1985-12-04 1994-04-06 Max Planck Gesellschaft Medicaments
GB8706313D0 (en) * 1987-03-17 1987-04-23 Health Lab Service Board Treatment & prevention of viral infections
US4965391A (en) 1987-10-23 1990-10-23 The University Of Michigan Radioiodinated phospholipid ether analogues
US5087721A (en) 1987-10-23 1992-02-11 The University Of Michigan Radioiodinated phosphate esters
US5138067A (en) 1987-12-17 1992-08-11 Shionogi & Co. Ltd. Lipid derivatives
WO1989006977A1 (en) 1988-02-04 1989-08-10 Board Of Regents, The University Of Texas System Formulation and use of retinoids in treatment of cancer and other diseases
EP0356765A3 (en) 1988-08-19 1991-08-07 Takeda Chemical Industries, Ltd. Carboxylic acid derivatives, their production and use
CA2001532A1 (en) 1988-10-27 1990-04-27 Hiroaki Nomura Lipids, their production and use
US5109118A (en) 1989-07-06 1992-04-28 Yutaka Mizushima Modified biologically active proteins
GB8928580D0 (en) 1989-12-19 1990-02-21 Scras 3-(n-methyl-n-alkylamino)-methoxymethyl-propanol phosphocholine derivatives
US5369097A (en) 1991-04-25 1994-11-29 The University Of British Columbia Phosphonates as anti-cancer agents

Also Published As

Publication number Publication date
CA2171281C (en) 1998-12-29
ATE244570T1 (de) 2003-07-15
DE69432930D1 (de) 2003-08-14
FI961109A0 (fi) 1996-03-08
ES2207639T3 (es) 2004-06-01
HK1007922A1 (en) 1999-04-30
NZ273258A (en) 2000-01-28
KR100260110B1 (ko) 2000-07-01
CA2171281A1 (en) 1995-03-16
FI961109A (fi) 1996-05-06
NO960907L (no) 1996-04-30
WO1995007089A1 (en) 1995-03-16
AU7648994A (en) 1995-03-27
JP4708511B2 (ja) 2011-06-22
EP0717631A1 (en) 1996-06-26
CN1132586C (zh) 2003-12-31
JPH09502706A (ja) 1997-03-18
DE69432930T2 (de) 2004-05-06
CN1136777A (zh) 1996-11-27
EP0717631B1 (en) 2003-07-09
US6280774B1 (en) 2001-08-28

Similar Documents

Publication Publication Date Title
NO960907D0 (no) Immunomoduleringssammensetninger fra galle
Yaron et al. Some recombinant human cytokines stimulate glycosaminoglycan synthesis in human synovial fibroblast cultures and inhibit it in human articular cartilage cultures
MX9602259A (es) Proteina modificada quimicamente en el nitrogeno terminal, composiciones que las incluyen y metodos para su preparacion.
NO974257L (no) Immunomodulerende preparater fra galle for behandling av immunsystemsykdommer
JO1365B1 (en) Laoxy repo nucleic polypeptide acid has a physiological activity on humans and includes a basic sequence for the coded arrangement of the said polypeptide and a method for producing this for polypeptide and the pharmacological composition included.
BG105764A (en) Artificial peptides having surface activity and the use thereof in the preparation of artificial surfactant
CA2193993A1 (en) New hil-4 mutant proteins used as antagonists or partial agonists of human interleukin 4
ES8608885A1 (es) Procedimiento para distinguir celulas normales de malignas, en una mezcla de las mismas
EP0291804A3 (de) Proteine mit TNF-Wirkung
RS89104A (en) Novel antagonists of mcp proteins
Seckinger et al. Modulation of the effects of interleukin‐1 on glycosaminoglycan synthesis by the urine‐derived interleukin‐1 inhibitor, but not by interleukin‐6
CA2094275A1 (en) Methods and compositions for the treatment of cell proliferation disorders
HUT65369A (en) Bcrf1 proteins as inhibitors of gamma-interferon
JPS6463395A (en) Oncostatin m and novel composition having antitumor activity
WO1997028255B1 (en) Immortal human prostate epithelial cell lines and clones and their applications in the research and therapy of prostate cancer
Kapp et al. Granulocyte-activating mediators (GRAM) II. Generation by human epidermal cells-relation to GM-CSF
Basu et al. Increased release of interleukin‐1 and tumour necrosis factor by interleukin‐2‐induced lymphokine‐activated killer cells in the presence of cisplatin and FK‐565
Kitano et al. Synthesis of the third component of complement (C3) by human gastric cancer-derived cell lines
Magielska-Zero et al. Comparison of the acute phase response of cultured Morris hepatoma 7777 cells and of rat hepatocytes.
MX9700113A (es) Amido-quinoxalindionas novedosas, su preparacion y uso.
MX9704729A (es) Monomeros de 4,4-(disustituido)ciclohexan-1-oles y compuestos relacionados.
EP0691347A4 (en) GROWTH SUBSTANCE FOR LIVER PARENCHYM CELLS
Decker et al. Porcine heart valves produce a protein that induces cell-mediated connective tissue degradation: II. Biochemical properties of the partially purified protein.
Dinarello et al. Role of arachidonate metabolism in the immunoregulatory function of human leukocytic pyrogen
Mizel et al. Interleukin 1 production by a human acute monocytic leukemia cell line (THP-1)

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application